*Actual product packaging may differ from the image shown.
Foundayo® (Orforglipron) (Oral Tablet)
Depending on the dose prescribed
$306.00–$531.00
Shop All Treatments
Foundayo (Orforglipron): The Once-Daily GLP-1 Pill, No Food or Water Rules
An FDA-approved oral GLP-1 for chronic weight management that fits into any part of your day.
Foundayo (orforglipron) is an FDA-approved, once-daily oral GLP-1 receptor agonist for chronic weight management. As a small-molecule, non-peptide GLP-1, it activates the same appetite-regulating pathway as injectable GLP-1s but in pill form, and it can be taken any time of day without food or water restrictions. It is used with a reduced-calorie diet and increased activity.
Physician-prescribed · FDA-approved branded medication · Dispensed by licensed US pharmacies · Ongoing care team support
- Orforglipron (Non-Peptide GLP-1 Receptor Agonist): A small-molecule GLP-1 receptor agonist that reduces appetite and slows gastric emptying, lowering calorie intake and body weight. Its non-peptide structure allows once-daily oral dosing without food or water restrictions.
Best for: Adults with obesity, or overweight with a weight-related condition, who want an oral GLP-1 and can commit to lifestyle changes alongside treatment.
Not recommended for: Anyone with a personal or family history of medullary thyroid cancer or MEN 2; people using another GLP-1 medicine; and those who are pregnant or planning pregnancy without provider guidance.
Gastrointestinal effects such as nausea, constipation, diarrhea, and vomiting are the most common and can cause dehydration. Like other GLP-1 medicines, orforglipron carries a boxed warning for thyroid C-cell tumors and precautions around pancreatitis, gallbladder disease, and low blood sugar when combined with certain diabetes medicines. Report severe or persistent symptoms to your care team.
- ¹ Adults lost about 11% of body weight at 72 weeks on the highest dose Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine, 2025;393(18) (ATTAIN-1, NCT05869903). (At 72 weeks, mean weight change was -11.2% at the highest dose versus -2.1% with placebo; the efficacy estimand showed about 12.4% loss.) → NEJM
- ² Lowered A1C by about 1.3 to 1.8% in adults with type 2 diabetes Foundayo (orforglipron) FDA approval history and clinical trial results. 2026 (ATTAIN-2, NCT05872620). (In adults with type 2 diabetes, orforglipron lowered A1C by 1.3% to 1.8% from a baseline of 8.1% across doses, with the highest dose producing about 10.5% weight loss.) → Drugs.com
- ³ The first oral GLP-1 pill that can be taken any time of day without food or water restrictions Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine, 2025;393(18). (Orforglipron is a small-molecule, non-peptide oral GLP-1 receptor agonist given once daily, without the food and water restrictions required by peptide oral GLP-1s.) → NEJM
How it Works With EHRX
The entire process is online. No waiting rooms. Just straightforward, medically guided care.
Step 1
Choose your treatment and complete checkout
You'll receive a confirmation email with next steps.
Step 2
Complete a brief medical consultation
Check your email for a link to a short intake form and link to a virtual consult with a licensed physician.
Step 3
A licensed provider reviews your consultation
If approved, your prescription is written and sent to the pharmacy. If not, you receive a full refund.
Step 4
Your pharmacy ships within 3–5 business days
Your medication is shipped directly to your door in temperature-controlled packaging.
What to know before you start.
Foundayo® (Orforglipron) (Oral Tablet) is a compounded medication prepared by a licensed pharmacy for individual patient use.
It has not been reviewed by the FDA for safety or efficacy, and is prescribed based on the clinical judgment of a qualified healthcare provider. Compounded drugs are permitted to be prescribed but are not FDA-approved for safety and efficacy.
Clinical Evidence
In the pivotal ATTAIN-1 trial, adults lost up to about 11% of body weight at 72 weeks on the highest dose (about 12.4% by the efficacy estimand) versus about 2% with placebo. In adults with type 2 diabetes (ATTAIN-2), orforglipron lowered A1C by 1.3% to 1.8% and improved cardiometabolic markers. Results build over months alongside diet and activity.
Frequently Asked Questions
We aim to provide absolute clarity regarding your biological data and personalized wellness protocols.
One tablet once daily, at any time of day, with or without food or water. Your provider will titrate the dose up over time to improve tolerability.
Orforglipron is a small-molecule pill, not a peptide, so it does not require fasting or water limits. Injectable GLP-1s and oral semaglutide have different administration rules.
Appetite changes often begin within weeks; weight loss builds over several months as the dose increases.
Anyone with a personal or family history of medullary thyroid cancer or MEN 2, or hypersensitivity to orforglipron. It should not be combined with other GLP-1 medicines.
Sometimes, but combining with insulin or sulfonylureas raises the risk of low blood sugar; your provider will adjust your regimen.
Coverage for weight-management medicines varies by plan; pricing and any manufacturer options are shared before you start.
Yes, at any time before your next shipment.
Yes. Your care team monitors your response and side effects and adjusts your dose as needed.
A neck lump, hoarseness, trouble swallowing, severe abdominal pain, or persistent vomiting should be reported promptly.
The next generation
of weight management.
Dual-incretin metabolic support — personalized to you.
